Eyepoint Pharmaceuticals Inc (EYPT) — Capital Reinvestment Ratio

Latest as of June 2023: 0.01x

Eyepoint Pharmaceuticals Inc (EYPT) has a Capital Reinvestment Ratio of 0.01x as of June 2023, meaning it reinvests 0% of its operating cash flow ($57.02 Million) in capital expenditures ($396.00K). Check Eyepoint Pharmaceuticals Inc (EYPT) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

$57.02 Million
USD

Capital Expenditures

$396.00K
USD

Data as of

Jun 2023
Most recent filing

Eyepoint Pharmaceuticals Inc Capital Reinvestment Ratio (2010–2023)

This chart tracks Eyepoint Pharmaceuticals Inc's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see Eyepoint Pharmaceuticals Inc (EYPT) cash conversion ratio.

Annual Capital Reinvestment Ratio for Eyepoint Pharmaceuticals Inc (2010–2023)

Year-by-year Capital Reinvestment Ratio for Eyepoint Pharmaceuticals Inc from 2010 to 2023. See Eyepoint Pharmaceuticals Inc (EYPT) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 1.86x $1.88 Million $3.48 Million ▲ +11780.6%
2015 0.02x $10.30 Million $161.00K ▲ +931.8%
2010 0.00x $9.90 Million $15.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow